Our next Life Sciences Dinner will take place on 11 June at Hotel du Vin in Cambridge, in partnership with Silicon Valley Bank and Taylor Wessing. This is the latest in a series of events offering an opportunity for business leaders of life sciences companies to meet with their peers for dinner and discussion in a relaxed atmosphere.
We will be joined by special guests Jason Mellad (Start Codon), Karolina Zapadka (Accelerate@Babraham) and Nate Mayfield (Illumina) to discuss how to make the most of accelerators to fast track your business growth.
Jason Mellad is CEO & Co-founder of Start Codon, a new Cambridge accelerator backed by investors including Cambridge Innovation Capital, Genetech, Babraham Bioscience Technologies, Jonathan Milner & Ian Tomlinson, seeking to support the most exciting pre-Series A life science and healthtech companies globally. Prior to Start Codon, Jason spent 5 years as CEO of Cambridge Epigenetix.
Karolina Zapadka leads Accelerate@Babraham, the bio-incubator and life science accelerator at Babraham Research Institute. A highly experienced biotech business developer, Karolina has been part of the Cambridge life science ecosystem for the past 8 years, including as a Facilitator on the Judge Institute’s Ignite Programme and as Chief of Staff for Innovation Forum.
Nate Mayfield is the Senior Director of Commercial Operations, Strategy and Inside Sales for Illumina business in the EMEA region, helping develop and deliver upon a multi-year commercial growth strategy. He is also involved in the Illumina Global Accelerator, advising early stage genomics companies with their commercialisation and development of go-to-market strategy.
Attendance at this dinner is by invitation for business leaders in growth life sciences companies. If you would like to find out more about this or future Life Sciences Dinners please contact Kerry Linsey or Iain Hopper.
Bailey Fisher Executive Search is pleased to have assisted Congenica with the search for a CFO, resulting in the appointment of Wendy Britten.
Congenica, the global provider of clinical genomics interpretation software, has announced the appointment of Wendy Britten as its new Chief Financial Officer, effective 1st September, 2018.
Wendy will have overall control and responsibility for all financial aspects of the business and will play a key role in business development and fundraising activities.
A finance professional with experience in senior financial leadership roles, Wendy joins Congenica from AstraZeneca, where she headed up the Group Finance Business Performance team, working with the Senior Executive team. Prior to this, her career at PricewaterhouseCoopers (PwC) started in Audit, progressing ultimately to Director of M&A in both London and New York. She is a qualified Chartered Accountant and holds a BSc in Mathematics from the University of Sheffield.
David Atkins, CEO of Congenica, said:
“I am delighted to welcome Wendy to Congenica. She joins our Senior Management team at a pivotal time in the Company’s development. She brings financial leadership and business development expertise, as we move forward commercially on the back of our successful series B financing last year. Her international experience will support our operational expansion in the UK and across Europe, China and the US.”
Dr Andy Richards, Chairman of Congenica, said:
“Mrs Britten’s ambitious and energetic outlook and considerable experience adds to our skills as Congenica continues its successful trajectory in the international genomics sector. Her appointment underlines our ambition to become a significant global player, providing a critical service that enables genomics to deliver on its promise in human healthcare.”
Led by CEO David Atkins the past year has seen significant advancements for Congenica, including a successful Series B funding round that raised USD $13.5M from leading China- and UK-based investors. Congenica’s gold-standard Sapientia™ clinical genomic analysis platform is currently routinely used by hundreds of clinicians as well as supporting several major projects globally – including Genomics England’s ground-breaking 100K Genomes Project and China’s national 100K wellness project.
Commenting on her appointment, Congenica’s new CFO Wendy Britten said:
“I am looking forward to the opportunities that joining the team at Congenica offers. With a strong commitment to positively impacting patient’s lives, Congenica is poised for substantial growth. The field of genomic medicine has the potential to revolutionise our approach to rare genetic disease diagnosis and management, as well as in other areas of personalised medicine.”